健脾益肾化痰方联合DP化疗方案治疗中晚期肺鳞癌的效果

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (545 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the effect of Jianpi Yishen Huatan Formula combined with Docetaxel+Cisplatin(DP) chemotherapy on middle-advanced stage lung squamous carcinoma. Methods A total of 80 middle-advanced stage lung squamous carcinoma patients admitted to the Department of Oncology, the First Affiliated Hospital of Guangxi University of Chinese Medicine from January 2018 to January 2020 were selected. According to the random number table method, they were divided into observation group and control group, with 40 case with each group. The control group was given DP chemotherapy, and the observation group was given Jianpi Yishen Huatan Formula combined with DP chemotherapy, 21 days was one cycle, and the treatment lasted for 4-6 consecutive cycles. The short-term effect, traditional Chinese medicine, syndrome score, immune function, and adverse reaction were compared between the two groups. Results The total effective rate and disease control rate of observation group were significantly higher than those of control group (P ＜ 0.05). After treatment, traditional Chinese medicine syndrome scores of two groups were significantly decreased compared with before treatment, and observation group was lower than control group (P ＜ 0.05). The CD3+, CD4+, and CD4+/CD8+ of two groups were significantly higher than before treatment, and observation group was higher than the control group (P ＜ 0.05). The CD8+ of two groups was significantly decreased compared with before treatment, and the observation group was significantly lower than the control group (P ＜ 0.05). Compared with control group, the rate of myelosuppression, liver and kidney damage, gastrointestinal reactions and cardiotoxicity in observation group were less than those of control group (P ＜ 0.05). Conclusion Jianpi Yishen Huatan Formula combined with DP chemotherapy treat with middle-advanced stage lung squamous carcinoma, can effectively control disease progression, reduce adverse reactions, and improve immune function.

Key words： Lung squamous carcinoma Jianpi Yishen Huatan Formula Docetaxel Cisplatin Immune function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Xinli WANG Zhiguang

Cite this article:

CHEN Xinli WANG Zhiguang. Effect of Jianpi Yishen Huatan Formula combined with DP chemotherapy on middle-advanced stage lung squamous carcinoma[J]. 中国医药导报, 2021, 18(29): 102-105.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I29/102

[1] Majem M，Juan O，Insa A，et al. SEOM clinical guidelines for the treatment of lung squamous carcinoma（2018）[J]. Clin Transl Oncol，2019，21（1）：3-17.
[2] Zhang XP，Han S，Zhou HJ，et al. TIMM50 promotes tumor progression via ERK signaling and predicts poor prognosis of lung squamous carcinoma patients [J]. Mol Carcinog，2019，58（8）：767-776.
[3] 林才志，胡乃强，赵海燕，等.救必应汤联合DP方案治疗晚期非小细胞肺癌临床疗效综合评价[J].中国实验方剂学杂志，2017，2（15）：184-190.
[4] 林才志，韩丹，李蕾，等.救必应汤加减联合DP化疗治疗晚期非小细胞肺癌的临床观察[J].辽宁中医杂志，2018， 45（10）：2119-2122.
[5] 周颖，柴可群，陈嘉斌，等.柴可群辨治早期肺癌医案举隅[J].浙江中医杂志，2019，54（4）：304-304.
[6] 张用，毕建平，皮国良，等.国际肺癌研究协会第八版国际肺癌TNM分期修订稿解读[J].肿瘤防治研究，2016， 43（4）：313-318.
[7] Ronot M，Bouattour M，Wassermann J，et al. Alternative Response Criteria （Choi，European association for the study of the liver，and modified Response Evaluation Criteria in Solid Tumors [RECIST]） Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib [J]. Oncologist，2014，19（4）：394-402.
[8] 中华人民共和国卫生部.中药新药临床研究指导原则[S].北京：人民卫生出版社，1993：130-131.
[9] 陈晓波，郝世凯，王玉亮，等.健脾益肾颗粒对Lewis肺癌小鼠免疫功能的影响[J].中国中西医结合杂志，2019， 39（2）：237-241.
[10] 刘殿龙，陈雨，崔述生，等.补脾调气法在非小细胞肺癌治疗中的应用[J].中国医药导报，2019，16（33）：133-136.
[11] 杨松，徐力.健脾除湿化痰方治疗气虚痰湿型非小细胞肺癌脑转移的效果及对患者生活质量的影响[J].中国医药导报，2020，17（23）： 138-141.
[12] 李恬，宋少莉，黄钢.中医药治疗肺癌的免疫机制研究进展及治疗现状[J].中医药学报，2020，48（1）：62-66.
[13] 江洋，王子卿，张弘，等.王沛治疗肺癌经验撷菁[J].辽宁中医杂志，2019，46（4）：696-698.
[14] 肖书楷，高启龙.高启龙运用风药辨治肺癌经验[J].中国民间疗法，2020，28（3）：18-20.
[15] 向明芝，曹勇，陈利国，等.曹勇教授运用健脾补肾祛瘀法治疗肺癌咳嗽经验[J].亚太传统医药，2020，16（1）：103-105.
[16] 周雯，曾亮，李艳.李艳教授的补土思想结合体质学说调治岭南人群失眠症的思路与经验总结[J].中医临床研究，2019，11（12）：11-13.
[17] 扈冰，龚亚斌.30位名中医辨证治疗肺癌经验述要[J].中医药导报，2018，308（10）：53-55.
[18] 姚逸临，李和根，陈智伟，等.健脾温肾软坚解毒方，康艾注射液联合低剂量化疗治疗老年脾肾两虚型晚期非小细胞肺癌的临床研究[J].上海中医药杂志，2020， 54（3）：67-71.
[19] 贺忠宁，张培彤.张培彤教授治疗化疗期原发性肺癌患者的临床经验[J].湖南中医药大学学报，2021，41（2），200-204.
[20] 王杰，胡钟竞.健脾补肾方对肺癌化疗后骨髓抑制的临床疗效观察[J].中医药临床杂志，2020，32（10）：105-108.
[21] 李跃军，卓德斌，贺海辉，等.益气复元汤联合化疗治疗晚期肺鳞癌的临床观察及对血浆Visfatin的影响[J].湖南中医杂志，2018，34（8）：12-15.
[22] 卢明清，周红梅，周旭光.贝伐单抗或血管内皮抑制素联合化疗治疗局部晚期EGFR野生型非小细胞肺癌的近期疗效及毒副反应[J].中国肿瘤生物治疗杂志，2019， 26（4）：67-71.
[23] 刘克元.顺铂联合长春瑞滨辅助化疗对行肺癌根治术后患者的临床疗效及毒副反应[J].中国医师杂志，2020， 22（3）：116-119.
[24] 闫睿.化疗与靶向治疗顺序对晚期进展性非小细胞肺癌患者进展及生存期的影响[J].中国现代医生，2021，59（1）：73-76.
[25] 詹峰，刘茜，何光照，等.CD3+CD4+T细胞和CD3+CD8+T细胞水平与晚期非小细胞肺癌患者预后的关系[J].医学临床研究，2020，37（1）：29-32.
[26] 彭姝蕾，陈蒙，李莹，等.GP化疗方案联合扶正消瘤方对EGFR-TKI获得性耐药的晚期非小细胞肺癌患者T淋巴细胞亚群和生活质量的影响[J].现代中西医结合杂志，2020，29（15）：1652-1656.
[27] 黄俊谦，王鹏，徐美华，等.MiR-151a-5p表达与晚期非小细胞肺癌患者病理特征、化疗效果的相关性及潜在靶基因的探究[J].临床和实验医学杂志，2020，19（19）：2057-2060.